A widely used over-the-counter drug, originally derived from willow bark, is now at the center of major medical attention. Aspirin is being studied for its surprising potential to reduce the risk of certain cancers and slow tumor development.
Strong Results in High-Risk Patients
The most compelling evidence comes from patients with Lynch syndrome, a genetic condition linked to an extremely high risk of colorectal cancer.
A major clinical trial led by Professor John Burn at Newcastle University found that a daily low dose of aspirin taken for two years cut the risk of bowel cancer by around 50% in participants.
Researchers reported that patients taking aspirin developed significantly fewer colorectal tumors compared to those who did not receive the drug.
How Aspirin May Fight Cancer
Scientists believe aspirin may work in two key ways:
- It blocks the COX-2 enzyme, which is linked to inflammation and abnormal cell growth
- It reduces blood clot formation, potentially exposing cancer cells to immune system attack
These mechanisms are now being studied as part of broader cancer prevention strategies.
Policy Changes Already Underway
The research is already influencing healthcare policy in some countries. Sweden has begun genetic screening for bowel cancer patients and offering low-dose aspirin to reduce recurrence risk.
In the UK, updated guidelines now recommend aspirin use for certain high-risk individuals under medical supervision.
Not a Risk-Free Solution
Despite promising results, experts warn that aspirin is not suitable for everyone. Regular use can lead to serious side effects, including:
- Internal bleeding
- Stomach ulcers
- Brain hemorrhage risks
Professor Anna Martling of the Karolinska Institute cautions against widespread use in healthy populations, emphasizing that benefits must be carefully weighed against risks.
Ongoing Global Trials
Large-scale trials involving more than 11,000 participants across the UK, Ireland, and India are currently investigating whether aspirin may also help prevent breast, prostate, and esophageal cancers.
Results from these studies are expected in 2027 and could further shape future cancer prevention guidelines.
A Promising but Complex Future
While aspirin may represent a major step forward in cancer prevention for high-risk groups, experts stress that it is not a universal solution. Careful medical supervision remains essential as research continues to uncover its full potential.
